Dr. Reddy’s Laboratories (NYSE:RDY) Stock Rating Lowered by StockNews.com

Dr. Reddy’s Laboratories (NYSE:RDY) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

Separately, Barclays dropped their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Trading Up 0.7 %

NYSE:RDY opened at $14.57 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories has a 12 month low of $12.90 and a 12 month high of $16.89. The company has a market cap of $12.16 billion, a PE ratio of 23.28 and a beta of 0.53. The company has a 50 day simple moving average of $15.02 and a two-hundred day simple moving average of $15.35.

Institutional Trading of Dr. Reddy’s Laboratories

A number of large investors have recently made changes to their positions in RDY. CWM LLC grew its holdings in Dr. Reddy’s Laboratories by 10.5% during the 2nd quarter. CWM LLC now owns 2,855 shares of the company’s stock valued at $218,000 after purchasing an additional 271 shares during the last quarter. QRG Capital Management Inc. boosted its position in Dr. Reddy’s Laboratories by 2.3% in the 2nd quarter. QRG Capital Management Inc. now owns 7,910 shares of the company’s stock valued at $603,000 after buying an additional 180 shares during the period. Artemis Investment Management LLP boosted its position in Dr. Reddy’s Laboratories by 92.6% in the 2nd quarter. Artemis Investment Management LLP now owns 15,600 shares of the company’s stock valued at $1,189,000 after buying an additional 7,500 shares during the period. Sequoia Financial Advisors LLC boosted its position in Dr. Reddy’s Laboratories by 7.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 15,607 shares of the company’s stock valued at $1,189,000 after buying an additional 1,081 shares during the period. Finally, V Square Quantitative Management LLC boosted its position in Dr. Reddy’s Laboratories by 46.1% in the 2nd quarter. V Square Quantitative Management LLC now owns 13,510 shares of the company’s stock valued at $1,020,000 after buying an additional 4,260 shares during the period. 14.02% of the stock is currently owned by institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.